501 results on '"Martin, Jarad"'
Search Results
2. The impact of a regionally based translational cancer research collaborative in Australia using the FAIT methodology
3. Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial
4. Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy
5. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial
6. Clinical validation of the Varian Truebeam intra-fraction motion review (IMR) system for prostate treatment guidance
7. Clinical target volume delineation quality assurance for MRI-guided prostate radiotherapy using deep learning with uncertainty estimation
8. Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost
9. Cone beam computed tomography image guidance within a magnetic resonance imaging-only planning workflow
10. Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy
11. Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer
12. Validation of an MRI-only planning workflow for definitive pelvic radiotherapy
13. Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)
14. Estimated incidence of disruptions to event-free survival from non-metastatic cancers in New South Wales, Australia - a population-wide epidemiological study of linked cancer registry and treatment data.
15. Fusion versus cognitive MRI-guided prostate biopsies in diagnosing clinically significant prostate cancer.
16. Population-Level Uptake of Moderately Hypofractionated Definitive Radiation Therapy in the Treatment of Prostate Cancer
17. Optimisation and validation of an integrated magnetic resonance imaging-only radiotherapy planning solution
18. Esophageal chemoradiotherapy with concurrent nivolumab: Pilot results in the palliative treatment of oligometastatic disease.
19. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial
20. Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial
21. Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials
22. Dosimetric impact of intrafraction rotations in stereotactic prostate radiotherapy: A subset analysis of the TROG 15.01 SPARK trial
23. Non‐contrast based approach for liver function quantification using Bayesian‐based intravoxel incoherent motion diffusion weighted imaging: A pilot study
24. Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials
25. Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method
26. The first clinical implementation of real-time image-guided adaptive radiotherapy using a standard linear accelerator
27. 1554: Automated contour quality assurance: Implementation and impact in the TROG18.01 NINJA Clinical Trial
28. 636: Dosimetric factors impacting urethral toxicity following stereotactic prostate radiotherapy
29. Prostate-Specific Membrane Antigen Positron Emission Tomography–Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning
30. The first clinical implementation of a real-time six degree of freedom target tracking system during radiation therapy based on Kilovoltage Intrafraction Monitoring (KIM)
31. Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).
32. Treatment de‐intensification for low‐risk biochemical recurrence after radical prostatectomy: rational or risky?
33. Virtual HDR Boost for Prostate Cancer: Rebooting a Classic Treatment Using Modern Tech
34. Automatic Substitute Computed Tomography Generation and Contouring for Magnetic Resonance Imaging (MRI)-Alone External Beam Radiation Therapy From Standard MRI Sequences
35. Optimizing Radiation Therapy Quality Assurance in Clinical Trials: A TROG 08.03 RAVES Substudy
36. FDG-PET parameters predict for recurrence in anal cancer – results from a prospective, multicentre clinical trial
37. Intratumoural renal cell carcinoma haemorrhage following stereotactic radiotherapy: a case report
38. Clinical validation of the Varian Truebeam intra-fraction motion review (IMR) system for prostate treatment guidance
39. Management of early anal cancer: need for guidelines and standardisation
40. Spinal multiparametric MRI and DEXA changes over time in men with prostate cancer treated with androgen deprivation therapy: a potential imaging biomarker of treatment toxicity
41. The dosimetric error due to uncorrected tumor rotation during real‐time adaptive prostate stereotactic body radiation therapy
42. Determination of hepatic extraction fraction with gadoxetate low‐temporal resolution DCE‐MRI ‐based deconvolution analysis: validation with ALBI score and Child‐Pugh class
43. 280. MULTI-OMIC FEATURES OF OESOPHAGEAL ADENOCARCINOMA PATIENTS PRE-TREATED WITH PREOPERATIVE NEOADJUVANT THERAPY
44. 204. THE TUMOUR IMMUNE MICROENVIRONMENT IN OESOPHAGEAL ADENOCARCINOMA HAS PROGNOSTIC SIGNIFICANCE
45. Fostering a culture of research within a clinical radiation oncology department
46. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II
47. PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol
48. The impact of contour variation on tumour control probability in anal cancer
49. Long-term outcome for prostate cancer using pseudo pulse–dosed rate brachytherapy, external beam radiotherapy, and hormones
50. Prostate radiotherapy clinical trial quality assurance: How real should real time review be? (A TROG-OCOG Intergroup Project)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.